Ozempic for Diabetes Prevention: Clinical Evidence & Personali...

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 receptor agonists like semaglutide demonstrate prevention potential in clinical trials. The SUSTAIN-6 and LEADER trials showed approximately 26% relative risk reduction in major cardiovascular events among patients with established type 2 diabetes. For diabetes prevention specifically, semaglutide showed robust delay or prevention of progression from prediabetes to diabetes in the STEP program.

Diabetes prevention is not one-size-fits-all. Your age, BMI, metabolic health markers, family history, and genetic predispositions all influence whether preventive GLP-1 therapy might be appropriate. PlexusDx helps patients and providers evaluate these factors together, using precision-wellness testing to support personalized prevention conversations.

How Semaglutide and GLP-1 Agonists Work to Prevent Diabetes Progression

GLP-1 receptor agonists regulate blood glucose by enhancing insulin secretion when glucose is elevated and slowing gastric emptying. They also reduce appetite and support weight loss—a key mechanism for diabetes prevention. Semaglutide activates GLP-1 receptors in the pancreas, brain, and gut, creating a multi-system effect that addresses prediabetes biology.

In the SUSTAIN 7 trial, patients on semaglutide showed mean weight loss of 6–10 kg, with corresponding improvements in fasting glucose and HbA1c. These metabolic shifts can help reverse insulin resistance, a primary driver of type 2 diabetes risk. However, medication alone does not replace diet, exercise, and lifestyle modifications.

Clinical Evidence for Diabetes Prevention: Key Trial Data and Population Groups

Multiple randomized controlled trials support GLP-1 use in diabetes prevention. The STEP trials enrolled overweight or obese adults without diabetes, demonstrating delayed progression to type 2 diabetes. The LEADER and SUSTAIN trials focused on established diabetes but provide safety and efficacy data relevant to prevention discussions. Below is a comparison of key evidence factors.

Evidence Factor	Key Finding
Primary Prevention Population	Overweight/obese adults with prediabetes; BMI ≥27 kg/m²
Risk Reduction	~26-30% relative reduction in diabetes progression or major CV events
Weight Loss Effect	Average 6–10 kg with semaglutide 1.0 mg weekly; correlates with glucose improvement
HbA1c Improvement	Typically 0.5–1.5% reduction in prediabetic patients within 6 months
Safety Profile	Common side effects: nausea, vomiting; generally mild to moderate and often transient
Study Duration	STEP trials: 68 weeks; SUSTAIN trials: 30–156 weeks depending on phase

Who May Benefit from Diabetes Prevention with GLP-1 Therapy: Clinical Eligibility

Candidates for diabetes prevention therapy typically have prediabetes (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%), BMI ≥27 kg/m², and additional risk factors such as family history, sedentary lifestyle, or metabolic syndrome. Age, ethnicity, and cardiovascular disease history also inform risk stratification. Your provider evaluates these factors holistically.

Not all prediabetic individuals require pharmacotherapy. Intensive lifestyle intervention—diet, exercise, weight loss of 5–10%—remains first-line for many. However, patients with multiple risk factors, prior diabetes diagnosis attempts, or rapid glucose decline may benefit from medication alongside lifestyle changes. This decision requires individualized clinical judgment.

Safety, Side Effects, and Who Should Not Use GLP-1 for Diabetes Prevention

GLP-1 agonists are generally well-tolerated but carry risks. Nausea, vomiting, and gastrointestinal symptoms occur in 30–40% of patients and often resolve within weeks. Rare but serious risks include pancreatitis and gallbladder issues. Contraindications include personal or family history of medullary thyroid cancer, type 1 diabetes, and severe renal impairment. Pregnancy is a relative contraindication.

Compounded semaglutide and tirzepatide from licensed 503A pharmacies are formulated under specific quality and stability standards. These are not FDA-approved brand medications, so interpretation of safety data relies on clinical experience and provider oversight. Discuss all medical history, medications, and allergies with your provider before initiation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 metabolic pathways—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—to provide genetic context for diabetes and obesity risk. These predispositions may help provide context for your individual metabolic biology and should be interpreted with a qualified healthcare provider when considering prevention strategies.

Genetic variants related to GLP-1 signaling and weight regulation can influence individual metabolic responses, but they do not predict exact medication response or guarantee outcomes. The Precision Peptide Genetic Test reveals predispositions in peptide genetic pathways, supporting more nuanced conversations about prevention candidacy and expected metabolic changes. This is not pharmacogenetic testing and does not replace clinical evaluation.

Combining genetic insights with traditional biomarkers—fasting glucose, HbA1c, insulin resistance, lipid profile, BMI—can support a more informed conversation with your provider about whether preventive GLP-1 therapy aligns with your biology and risk profile. This precision-wellness approach helps inform shared decision-making around prevention options and compounded medication choices.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.